Hossny Elham, Caraballo Luis, Casale Thomas, El-Gamal Yehia, Rosenwasser Lanny
Pediatric Allergy and Immunology Unit, Children's Hospital Ain Shams University, 40A Baghdad Street, Cairo, 11341 Egypt.
Institute for Immunological Research, University of Cartagena, Cartagena, Colombia.
World Allergy Organ J. 2017 Aug 21;10(1):28. doi: 10.1186/s40413-017-0159-y. eCollection 2017.
Severe asthma has a great impact on the quality of life (QOL) of patients and their families. The magnitude of this morbidity is affected by several personal factors including age. Appropriate asthma control and modifications of social roles and activities are expected to improve QOL. Biologics, primarily monoclonal antibodies, have been developed to target specific pathways and molecules important in the pathogenesis of asthma. The use of biologics has shown some promising effects on the QOL of patients with severe recalcitrant asthma. Other potential measures involve targeting risk factors and comorbidities and improving the levels of adherence to therapy. This article briefly reviews the impact of severe asthma on QOL and the potential methods to combat this morbidity including the available therapeutic biologics.
重度哮喘对患者及其家庭的生活质量（QOL）有很大影响。这种发病率的严重程度受包括年龄在内的多种个人因素影响。适当的哮喘控制以及社会角色和活动的调整有望改善生活质量。生物制剂，主要是单克隆抗体，已被开发用于靶向哮喘发病机制中重要的特定途径和分子。生物制剂的使用已显示出对重度顽固性哮喘患者的生活质量有一些有前景的效果。其他潜在措施包括针对危险因素和合并症以及提高治疗依从性水平。本文简要综述了重度哮喘对生活质量的影响以及对抗这种发病率的潜在方法，包括现有的治疗性生物制剂。
